Theseus Pharmaceuticals, Inc. (THRX)
| Market Cap | 177.04M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -56.61M |
| Shares Out | 43.61M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,402,078 |
| Open | 4.060 |
| Previous Close | 4.060 |
| Day's Range | 4.060 - 4.060 |
| 52-Week Range | 2.050 - 12.370 |
| Beta | 3.98 |
| Analysts | Strong Buy |
| Price Target | 11.75 (+189.41%) |
| Earnings Date | Mar 7, 2024 |
About THRX
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development prog... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for THRX stock is "Strong Buy." The 12-month stock price forecast is $11.75, which is an increase of 189.41% from the latest price.
News
Theseus Pharmaceuticals Announces Closing of Tender Offer
-- Theseus Stockholders to Receive $4.05 Per Share in Cash Plus Contingent Value Right -- CAMBRIDGE, Mass. , Feb. 14, 2024 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or th...
Concentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--As previously announced on December 22, 2023, Concentra Biosciences, LLC (“Parent”) and its wholly owned subsidiary, Concentra Merger Sub II, Inc. (“Purchaser”), entered in...
THESEUS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS , Jan. 22, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmace...
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right
CAMBRIDGE, Mass. , Dec. 22, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of...
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
CAMBRIDGE, Mass. , Nov. 27, 2023 /PRNewswire/ -- On November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicit...
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of can...
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare Conference
CAMBRIDGE, Mass. , Nov. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of canc...
Theseus Pharmaceuticals: Picking Up The Pieces After A Lead Failure
Theseus Pharmaceuticals experienced significant losses after discontinuing its lead program, leaving it with a market cap of half of its current assets. THRX is now focusing on developing a fourth-gen...
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024 Nomination of highly selective pan-varia...
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This MonthSilk Road Me
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Theseus Pharmaceuticals stock plummets after cancer drug development stopped
Theseus Pharmaceuticals Inc. THRX, -3.74% shares plummeted after hours Thursday after the biotech drug maker discontinued enrolling patients in the study of a cancer drug it no longer intend to develo...
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
-- Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) -- -- Company prioritizing THE-349, a potentially best-in-class fourth-generation EGFR ...
Theseus Pharmaceuticals to Participate in the Jefferies Healthcare Conference
CAMBRIDGE, Mass. , May 31, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients t...
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for b...
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 -- -- IND submission for THE-349 in EGFR-mutant NSCL...
Theseus Pharmaceuticals: Orbimed-Backed Ex-ARIAD Team Developing Next-Gen TKI
Theseus Pharmaceuticals, Inc. is a small company with large dreams backed by $100mn from Orbimed before it went public. The idea is to create pan-variant TKIs that can address all sorts of tumor resis...
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass. , April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus...
Theseus Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients...
Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium
CAMBRIDGE, Mass. , March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients...
Theseus Pharmaceuticals Announces Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
THE-630 phase 1 preliminary dose-escalation data anticipated in Q2 2023; additional data including dose levels projected preclinically to provide pan-variant KIT coverage planned for Q4 2023 IND submi...
Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
CAMBRIDGE, Mass. , Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients t...
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program
Progressing Phase 1/2 clinical trial of THE-630 in advanced GIST; preliminary dose-escalation data anticipated in Q2 2023 with additional data expected in Q4 2023 IND submission for 4G EGFR inhibitor ...
Theseus Pharmaceuticals Presents Preclinical Data Characterizing THE-349, its Fourth-Generation EGFR Inhibitor in Development for NSCLC, at the 34th EORTC-NCI-AACR Symposium
Potent single-molecule inhibition of all major classes of EGFR activating and resistance mutations, including C797X and T790M, with a high degree of kinome and wild-type EGFR selectivity Deep and dura...
Theseus Pharmaceuticals Appoints Steven Stein, M.D. to Board of Directors
CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of can...